<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Mito Laboratories — Disease focus</title>
  <meta name="description" content="Disease areas targeted by Mito Laboratories: high unmet-need cancers where mitochondrial and metabolic control may drive meaningful outcomes." />
  <link rel="stylesheet" href="styles.css" />

</head>
<body>
<a class="skip-link" href="#main">Skip to content</a>
<header class="site-header">
  <div class="nav-shell">
    <a class="brand" href="index.html">
      <div class="brand-mark" aria-hidden="true"></div>
      <div class="brand-name">
        <strong>MITO LABORATORIES</strong>
        <span>Protocolised mitochondrial biology</span>
      </div>
    </a>

    <button class="nav-toggle" type="button" data-nav-toggle aria-expanded="false" aria-controls="primary-nav">
      Menu
    </button>

    <nav id="primary-nav" class="nav-links" data-nav-links aria-label="Primary navigation">
      <a class="nav-link" href="index.html">Home</a>

   <!-- Our Company dropdown -->
<div class="nav-item has-dropdown">
  <a class="nav-link" href="company-about.html"
     data-dropdown-toggle
     aria-expanded="false"
     aria-controls="company-menu">
    Our Company <span class="chev" aria-hidden="true"></span>
  </a>

  <div class="dropdown" id="company-menu" role="menu" aria-label="Our Company">
    <a class="dropdown-link" role="menuitem" href="company-about.html">About us</a>
    <a class="dropdown-link" role="menuitem" href="company-team.html">Meet our team</a>
    <a class="dropdown-link" role="menuitem" href="company-news.html">News &amp; Events</a>
  </div>
</div>

<!-- Science dropdown -->
<div class="nav-item has-dropdown">
  <a class="nav-link" href="science.html"
     data-dropdown-toggle
     aria-expanded="false"
     aria-controls="science-menu">
    Science <span class="chev" aria-hidden="true"></span>
  </a>

  <div class="dropdown" id="science-menu" role="menu" aria-label="Science">
    <a class="dropdown-link" role="menuitem" href="pipeline.html">Pipeline</a>
    <a class="dropdown-link" role="menuitem" href="science.html">Philosophy</a>
    <a class="dropdown-link" role="menuitem" href="disease-focus.html">Disease focus</a>
  </div>
</div>


      <a class="nav-link nav-cta" href="mailto:info@mitolaboratories.com">Contact</a>
    </nav>
  </div>
</header>


<main id="main">
  <section class="hero">
    <div class="container hero-grid">
      <div>
        <div class="kicker"><b>Disease focus</b> · high unmet need oncology</div>
        <h1>Prioritising cancers where new metabolic strategies are most needed.</h1>
        <p>
          We focus on tumour types with persistently poor outcomes, where metabolic and mitochondrial adaptation can be a
          major driver of survival, therapy resistance, and immune evasion. Our goal is to translate mitochondria-centric
          insights into measurable, protocolised programs.
        </p>
        <div class="btn-row">
          <a class="btn primary" href="pipeline.html">View pipeline</a>
          <a class="btn" href="science.html">Scientific platform</a>
        </div>
      </div>

      <aside class="hero-card" aria-label="Indication selection criteria">
        <div class="hero-img" style="background-image:url('assets/hero-home.svg')"></div>
        <div class="hero-meta">
          <h3 style="margin:0 0 8px;font-size:16px;">Selection criteria</h3>
          <ul class="list">
            <li>High unmet need and limited durable responses</li>
            <li>Clear mitochondrial/metabolic dysregulation signals</li>
            <li>Feasible translational biomarkers for early readouts</li>
            <li>Path to protocolised clinical evaluation</li>
          </ul>
        </div>
      </aside>
    </div>
  </section>

  <section class="section">
    <div class="container">
      <h2>Why these cancers</h2>
      <p>
        Many solid tumours with poor survival demonstrate strong metabolic plasticity: they rewire energy production,
        redox balance, and nutrient utilisation to thrive under hypoxia, immune pressure, and therapy. Because mitochondria
        integrate these processes with apoptosis signalling and stress responses, a mitochondria-centric strategy may provide
        a differentiated way to identify vulnerabilities and design combinable interventions.
      </p>

      <p>
        We are primarily interested in cancers with low five-year survival rates and high treatment resistance. These are
        areas where improved mechanistic understanding and disciplined, measurement-first development can have meaningful impact.
      </p>

      <div class="grid-3">
        <div class="card">
          <h3>Pancreatic cancer</h3>
          <p>High metabolic adaptability and stromal constraints; need for new vulnerability-driven strategies.</p>
        </div>
        <div class="card">
          <h3>Liver cancer</h3>
          <p>Complex metabolic environment and immune context; opportunities for biomarker-guided approaches.</p>
        </div>
        <div class="card">
          <h3>Oesophageal cancer</h3>
          <p>Often diagnosed late with aggressive biology; rationale for targeting stress tolerance pathways.</p>
        </div>
        <div class="card">
          <h3>Brain cancers</h3>
          <p>Therapy resistance and microenvironment constraints; require strong mechanistic and delivery-aware development.</p>
        </div>
        <div class="card">
          <h3>Stomach (gastric) cancer</h3>
          <p>Heterogeneous disease with metabolic dependencies in subsets; opportunity for stratified programs.</p>
        </div>
        <div class="card">
          <h3>Program expansion</h3>
          <p>As data mature, we will expand indications based on biomarker fit and translational feasibility.</p>
        </div>
      </div>

      <hr class="hr" />

      <h2>What “layered metabolic strategy” means</h2>
      <p>
        We believe a layered approach to metabolic targeting can improve the probability of durable responses by addressing
        tumour survival from multiple angles. Practically, this means building programs that combine:
      </p>

      <ul class="list">
        <li><strong>Cell-fate leverage</strong> — shifting apoptotic priming and stress signalling</li>
        <li><strong>Metabolic constraints</strong> — limiting escape routes such as glycolysis dominance or lactate coupling</li>
        <li><strong>Microenvironment compatibility</strong> — reducing factors that support immune suppression and invasion</li>
        <li><strong>Protocolised execution</strong> — predefined biomarkers, dosing logic, and milestone-driven escalation</li>
      </ul>

      <hr class="hr" />

      <h2>How we translate into programs</h2>
      <p>
        Indications are selected based on a combination of biology, feasibility, and measurement. Our development approach
        is built to generate early, decision-quality evidence — not just mechanistic narratives.
      </p>

      <div class="grid-3">
        <div class="card">
          <h3>Biomarker-first design</h3>
          <p>Define measurable readouts of mitochondrial/metabolic state early to guide selection and dosing.</p>
        </div>
        <div class="card">
          <h3>Stratification hypotheses</h3>
          <p>Where possible, identify patient subsets most likely to benefit based on biology and biomarkers.</p>
        </div>
        <div class="card">
          <h3>Combination readiness</h3>
          <p>Design programs to be combinable with standard-of-care and immune approaches as data support.</p>
        </div>
      </div>

      <hr class="hr" />

      <h2>Responsible communication</h2>
      <p style="color:var(--muted);margin-bottom:0;">
        We aim to be ambitious but rigorous. Programs are hypothesis-driven and milestone-gated, with claims anchored to
        measurable validation and a clear translational plan.
      </p>
    </div>
  </section>
</main>

<footer class="footer">
  <div class="container">© 2026 Mito Laboratories. All rights reserved.</div>
</footer>

<script src="script.js"></script>
</body>
</html>
